PROteolysis-TArgeting Chimeras (PROTACs) are a revolutionary targeted protein degradation strategy. To date, several PROTACs that degrade leukemic oncoproteins have successfully overcome many of the limitations of conventional therapies. Although recent, the already enormous potential presented by PROTACs has aroused growing global interest, both from academia and industry, which coul... https://www.pharmafocusamerica.com/articles/protacs-in-leukemia-a-novel-drug-discovery-strategy-from-lab-bench-to-the-pharmaceutical-market